An exploratory analysis of a phase II study (NCT01439568) (181) assessed the utility of CXCR4 expression in circulating tumor cells as a prognostic biomarker in 89 lung cancer patients (61, 62, 136, 139). Here, CXCR4 is linked to neoplasm.